英派药业 | IMPACT Therapeutics Make an IMPACT on Cancer Treatment Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients
英派药业 | IMPACT Therapeutics 英派药业官方网站 Make an IMPACT on Cancer Treatment 英派药业成立于2009年，是一家处于商业化阶段的生物技术公司，致力于在全球范围内推进基于合成致死机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。公司通过自主研发建立了最全面、最先进的合成致死产品组合之一，也是
英派药业 | IMPACT Therapeutics Address: 27F, Qiantan Times Square, No 399 Haiyang West Road, Pudong New Area, Shanghai Hotline: 400-008-4297 AE Reporting: MAHPV@impacttherapeutics com email: info@impacttherapeutics com
IMPACT Announces Results of Senaparib for PSOC at ESMO2025 About IMPACT Therapeutics Founded in 2009, IMPACT Therapeutics is a commercial-stage, innovation-driven biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally to redefine standard of care
IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for . . . IMPACT Therapeutics, in collaboration with our partner Junshi Biosciences, will communicate with regulatory authorities regarding a new drug application for Senaparib in the near future Dr Sui Xiong CAI, Chief Executive Officer of IMPACT Therapeutics, commented on the positive results of the FLAMES study
IMPACT Announces Completion of RMB 250 million Sr. D++ Financing SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D++ financing of RMB 250 million